Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Neuro-Biotech Corporation introduces a Neuro-biomarker which is linked to a series of Neuro-Bio tests. This will permit to understand the science behind them and how they each will contribute to a progressive clinical investigation involving the input and output of the brain.

5 Oct 2010

NIEHS awards grant to study environmental impact on genetic information

The National Institute of Environmental Health Sciences has awarded $2.27 million to Indiana University researcher Joseph Shaw for a five-year study of how the environment alters genetic information through mutation and natural selection.

5 Oct 2010

Second pathway to brain’s memory function uncovered

Australian and US scientists have successfully identified a new mechanism by which the brain learns and stores memories. This could spell hope for brain injuries and diseases like Alzheimer’s disease.

4 Oct 2010

New SymPath kit measures DBH activity of Sympathetic Nervous System

Biotech Corporation in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

4 Oct 2010

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

A UC Irvine infectious disease specialist has received a three-year, $10 million grant to explore the effectiveness of new methods to prevent staph infections in people who harbor MRSA bacteria when they're discharged from the hospital.

4 Oct 2010

Welch Allyn launches Connex ProBP handheld automated digital blood pressure device

Welch Allyn, a leading global provider of frontline medical products and solutions, today introduced the Connex® ProBP™ 3400, an automated digital blood pressure device designed to fit in the palm of the hand. Borrowing Welch Allyn SureBP™ technology from the company's multiparameter vital signs devices, the Connex ProBP delivers fast, accurate blood pressure readings with the durability of Welch Allyn's popular hospital-grade vital signs devices.

4 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

Family and friends may pose the greatest threat to caregivers' health and well-being

The biggest cause of stress for people who care for loved ones after a stroke may not be worrying about the affected family member.

1 Oct 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

Study suggests H2O2 can act as anti-inflammatory compound

A major blow to the free radical theory of aging, which had lead the research in aging for more than 50 years and fuels a multimillionaire anti-aging industry has just been published by Portuguese scientists from the University of Minho. According to the theory, free radicals provoke oxidative damage and this is the cause of aging.

30 Sep 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

McLean Researchers receive award to create first clinic-ready human induced iPS cells

Belmont, MA-Researchers at Harvard Affiliated McLean Hospital have been awarded a $1.9 million National Institutes of Health Director's Opportunity Award to continue their research into creating human induced pluripotent (iPS) stem cells using a method aimed at eliminating the risk of cancer and other problems associated with other options such as genome-integrating viral methods.

30 Sep 2010

UTHealth researcher receives grant to develop biochemical diagnosis test for Alzheimer's disease

The Alzheimer's Association has awarded a three-year, $200,000 grant to Claudio Soto, Ph.D., professor of neurology at The University of Texas Health Science Center at Houston (UTHealth), to pursue a procedure that could detect pre-symptomatic Alzheimer's disease.

30 Sep 2010

COE on Brain Aging at NYU Langone establishes Lewy Body Disease Center

The Center of Excellence (COE) on Brain Aging at NYU Langone Medical Center has established a specialty center for the diagnosis and treatment of Lewy Body Disease, a multi-system disease involving disturbances of cognition, behavior, sleep and autonomic function. Lewy Body Disease, or LBD, affects an estimated 1.3 million individuals in the United States and is widely misdiagnosed because LBD symptoms closely resemble those of other more commonly known diseases such as Alzheimer's and Parkinson's disease.

30 Sep 2010

Research shows dexamethasone treatment effective for bacterial meningitis

New research shows that an intravenous (IV) treatment may cut a person's risk of dying from bacterial meningitis. The research is published in the September 29, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology. The treatment is called dexamethasone.

30 Sep 2010

Memantine enhances language and communication skills in patients with Alzheimer's disease

Memantine enhances language and communication skills in patients with moderate to severe Alzheimer’s disease (AD), a valuable contribution for patient independence and quality of life for both the patient and the family/caregivers. These are the findings discussed at the 14th Congress of the European Federation of Neurological Societies (EFNS).

30 Sep 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

New topical microbicide gel can prevent HIV transmission

Amyloid protein structures are best known for the troubles they pose in the brains of Alzheimer's patients. Now researchers are trying to exploit their presence in a very different place in semen to find a new way to stop HIV.

29 Sep 2010

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Synosia Therapeutics today announced the first clinical study results showing that SYN-118 provides clinically meaningful benefits to Parkinson's patients, has a good safety profile and is well tolerated. Results from an open-label, proof-of-mechanism study of SYN-118 (CL02) were presented at the World Parkinson Congress in Glasgow, Scotland.

29 Sep 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

NIEHS awards grant to study environmental impact on genetic information

Second pathway to brain’s memory function uncovered

New SymPath kit measures DBH activity of Sympathetic Nervous System

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

Welch Allyn launches Connex ProBP handheld automated digital blood pressure device

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Family and friends may pose the greatest threat to caregivers' health and well-being

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

Study suggests H2O2 can act as anti-inflammatory compound

Penn Medicine selected as study site for PPMI

McLean Researchers receive award to create first clinic-ready human induced iPS cells

UTHealth researcher receives grant to develop biochemical diagnosis test for Alzheimer's disease

COE on Brain Aging at NYU Langone establishes Lewy Body Disease Center

Research shows dexamethasone treatment effective for bacterial meningitis

Memantine enhances language and communication skills in patients with Alzheimer's disease

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

New topical microbicide gel can prevent HIV transmission

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in